220 related articles for article (PubMed ID: 29738555)
1. Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.
Sirois AR; Deny DA; Baierl SR; George KS; Moore SJ
PLoS One; 2018; 13(5):e0197029. PubMed ID: 29738555
[TBL] [Abstract][Full Text] [Related]
2. Engineered Fn3 protein has targeted therapeutic effect on mesothelin-expressing cancer cells and increases tumor cell sensitivity to chemotherapy.
Sirois AR; Deny DA; Li Y; Fall YD; Moore SJ
Biotechnol Bioeng; 2020 Feb; 117(2):330-341. PubMed ID: 31631324
[TBL] [Abstract][Full Text] [Related]
3. The role of mesothelin in tumor progression and targeted therapy.
Tang Z; Qian M; Ho M
Anticancer Agents Med Chem; 2013 Feb; 13(2):276-80. PubMed ID: 22721387
[TBL] [Abstract][Full Text] [Related]
4. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
5. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.
Feng Y; Xiao X; Zhu Z; Streaker E; Ho M; Pastan I; Dimitrov DS
Mol Cancer Ther; 2009 May; 8(5):1113-8. PubMed ID: 19417159
[TBL] [Abstract][Full Text] [Related]
6. Anti-Mesothelin Nanobodies for Both Conventional and Nanoparticle-Based Biomedical Applications.
Prantner AM; Turini M; Kerfelec B; Joshi S; Baty D; Chames P; Scholler N
J Biomed Nanotechnol; 2015 Jul; 11(7):1201-12. PubMed ID: 26307843
[TBL] [Abstract][Full Text] [Related]
7. Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody.
Prantner AM; Yin C; Kamat K; Sharma K; Lowenthal AC; Madrid PB; Scholler N
Mol Pharm; 2018 Apr; 15(4):1403-1411. PubMed ID: 29462558
[TBL] [Abstract][Full Text] [Related]
8. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
[TBL] [Abstract][Full Text] [Related]
9. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.
Zhang YF; Phung Y; Gao W; Kawa S; Hassan R; Pastan I; Ho M
Sci Rep; 2015 May; 5():9928. PubMed ID: 25996440
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
11. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
Rump A; Morikawa Y; Tanaka M; Minami S; Umesaki N; Takeuchi M; Miyajima A
J Biol Chem; 2004 Mar; 279(10):9190-8. PubMed ID: 14676194
[TBL] [Abstract][Full Text] [Related]
12. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.
Nichetti F; Marra A; Corti F; Guidi A; Raimondi A; Prinzi N; de Braud F; Pusceddu S
Target Oncol; 2018 Jun; 13(3):333-351. PubMed ID: 29656320
[TBL] [Abstract][Full Text] [Related]
13. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.
Scholler N; Garvik B; Hayden-Ledbetter M; Kline T; Urban N
Cancer Lett; 2007 Mar; 247(1):130-6. PubMed ID: 16677756
[TBL] [Abstract][Full Text] [Related]
14. FN3 Protein Conjugates for Cancer Diagnosis and Imaging Studies.
Natarajan A; Abou-Elkacem L
Methods Mol Biol; 2019; 2033():301-313. PubMed ID: 31332762
[TBL] [Abstract][Full Text] [Related]
15. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
[TBL] [Abstract][Full Text] [Related]
16. Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells.
Lazzerini L; Jöhrens K; Sehouli J; Cichon G
Arch Gynecol Obstet; 2020 Nov; 302(5):1255-1262. PubMed ID: 32815024
[TBL] [Abstract][Full Text] [Related]
17. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment.
Bergan L; Gross JA; Nevin B; Urban N; Scholler N
Cancer Lett; 2007 Oct; 255(2):263-74. PubMed ID: 17560019
[TBL] [Abstract][Full Text] [Related]
18. NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects.
Nicolaides NC; Kline JB; Grasso L
PLoS One; 2023; 18(5):e0285161. PubMed ID: 37195923
[TBL] [Abstract][Full Text] [Related]
19. Mesothelin as a target for cervical cancer therapy.
Jöhrens K; Lazzerini L; Barinoff J; Sehouli J; Cichon G
Arch Gynecol Obstet; 2019 Jan; 299(1):211-216. PubMed ID: 30324544
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan R; Ebel W; Routhier EL; Patel R; Kline JB; Zhang J; Chao Q; Jacob S; Turchin H; Gibbs L; Phillips MD; Mudali S; Iacobuzio-Donahue C; Jaffee EM; Moreno M; Pastan I; Sass PM; Nicolaides NC; Grasso L
Cancer Immun; 2007 Dec; 7():20. PubMed ID: 18088084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
